1. Home
  2. CRNC vs CAPR Comparison

CRNC vs CAPR Comparison

Compare CRNC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cerence Inc.

CRNC

Cerence Inc.

HOLD

Current Price

$11.33

Market Cap

362.2M

Sector

Technology

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$29.72

Market Cap

324.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNC
CAPR
Founded
2020
2005
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
362.2M
324.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CRNC
CAPR
Price
$11.33
$29.72
Analyst Decision
Buy
Strong Buy
Analyst Count
4
8
Target Price
$11.50
$41.38
AVG Volume (30 Days)
1.0M
5.4M
Earning Date
02-05-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$251,781,000.00
$11,130,509.00
Revenue This Year
$27.55
N/A
Revenue Next Year
N/A
$16,329.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.94
$4.30
52 Week High
$27.50
$40.37

Technical Indicators

Market Signals
Indicator
CRNC
CAPR
Relative Strength Index (RSI) 52.52 73.78
Support Level $10.87 $25.60
Resistance Level $11.65 $30.00
Average True Range (ATR) 0.57 1.92
MACD -0.07 -0.02
Stochastic Oscillator 29.23 69.91

Price Performance

Historical Comparison
CRNC
CAPR

About CRNC Cerence Inc.

Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: